Immune checkpoint inhibitors have been developed to combat T-cell exhaustion by blocking inhibitory receptors such as PD-1 and CTLA-4, and, thereby, reinvigorating the T-cells and enhancing the anti-tumour immune response (Budimir et al. The gene discussed is CTLA4; the disease is neoplasm.